Navigation Links
Biovista and the CFIDS Association of America Achieve Drug Repositioning Milestone with Pre-IND Meeting
Date:5/29/2013

CHARLOTTESVILLE, Virginia and CHARLOTTE, North Carolina, May 29, 2013 /PRNewswire/ --

Biovista and the CFIDS Association of America announced today the successful completion of the first phase of their collaboration. Funded as part of the CFIDS' Research Institute Without Walls, Biovista identified candidate treatments for CFS using its state-of-the-art COSS approach. Two candidate treatments, including a combination therapy, were identified and are being prepared for proof-of-concept clinical trials, with an FDA pre-IND meeting scheduled in Q3 2013.

"We are very excited to have reached this stage within a year of starting our collaboration. We look forward to furthering our understanding of this complex disease and developing a treatment that will improve CFS patients' quality of life," said Dr. Andreas Persidis , Biovista's CEO. "Our work is an example of things to come in terms of novel collaboration models that promise to accelerate treatment development and, through the drug repositioning approach, do so cost effectively," Dr Persidis added.

"There is a big gap in the pipeline that moves basic laboratory research into safe and effective treatments. Without a bridge to bring discoveries to the clinic, laboratory research rarely becomes more than a paper. We are providing the means for basic researchers to move discoveries through the translational research pipeline with our Research Institute Without Walls," said Kim McCleary , president and CEO of CFIDS.

"Therapies for ME/CFS are an unmet medical need. This is largely due to the lack of translating the scientific knowledge into meaningful impact for patients," added Dr. Suzanne D. Vernon , Scientific Director of CFIDS. "We understand the ME/CFS knowledgebase and know how to fill this gap. Biovista recognized the opportunity for discovery. This drug repositioning project is an excellent example of effective use of existing information to make a new treatment discovery."

About Biovista

Biovista finds novel uses for existing drugs and profiles their side effects using mechanism of action analysis. Biovista develops its own pipeline in CNS, oncology, auto-immune and rare diseases and collaborates with biopharmaceutical companies and Patient Groups on indication expansion, portfolio de-risking, and adverse event prediction. (http://www.biovista.com).

About CFIDS

The CFIDS Association of America is at the leading edge of ME/CFS research. For more information, please visit The Association's web site at http://www.cfids.org or their research blog at http://www.Research1st.org

Contacts
Biovista
Dr. Andreas Persidis
andreasp@biovista.com
T: +1-434-242-6514
 
The CFIDS Association of America
Dr. Suzanne D. Vernon
sdvernon@cfids.org


'/>"/>
SOURCE Biovista
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
2. Bayer Employees Named Rising Stars by Healthcare Businesswomens Association
3. Washington State Medical Association (WSMA) Urges Adults to Get Recommended Immunizations
4. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
5. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
6. Percutaneous Tibial Nerve Stimulation Included in the American Urological Associations Overactive Bladder Clinical Treatment Guidelines
7. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
8. Health Diagnostic Laboratory, Inc. Provides Grant to Support National Lipid Association, Sponsors 2012 Annual Scientific Sessions in Scottsdale, Arizona
9. Attack on the Website of the American Pharmacists Association
10. China Botanic Sponsors Wild Plant Protection Association of China Meeting; Expects to Lead the Siberian Ginseng Conservation Association
11. CyberKnife® Prostate SBRT Outcomes and Quality of Life Data Presented at American Urological Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... 2016  Breckenridge Pharmaceutical, Inc. announced today that ... with development and manufacturing partner Gland Pharma Limited ... of this agreement, Breckenridge will market and distribute ... the United States . The deal includes ... products cover a wide range of indications.  This ...
(Date:12/5/2016)... Oregon and PUNE, India , ... new report by Allied Market Research, titled, "Global Cancer Biomarkers ... global revenue of cancer biomarkers market is projected to reach ... a CAGR of 13.3% from 2016 to 2022. Omic technologies ... in 2015 and is expected to maintain its dominance during ...
(Date:12/5/2016)... Dec. 5, 2016  Recently Zymo Research announced ... predictor, known as Horvath,s Clock. Based on this ... analysis service to academic and biopharma scientific researchers ... sample, other than sperm. The service ... biological age versus chronological age following drug treatments ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... The ... formally announce its Not a Moment to Lose fundraising campaign. As the V ... dedicated to declaring victory over cancer. The campaign aims to raise $200 million ...
(Date:12/6/2016)... Pittsburgh, PA (PRWEB) , ... December 06, 2016 ... ... particle identification and characterization laboratories, is now offering HIAC particle counting and sizing ... available immediately. , Gateway Analytical instituted the new service as a response to ...
(Date:12/6/2016)... Switzerland (PRWEB) , ... December 06, 2016 , ... ... a one-stop portal for all the knowledge resources, including white papers, guides, ... certificates, and more. , To access more than 9,000 documents, webinars and ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble powder supplement has a ... world’s most powerful antioxidants, molecular hydrogen, HydroFX for Water transforms every day ...
(Date:12/6/2016)... ... ... Keeping Gift Season Safe, In a season stacked with gift-giving opportunities, it's ... recipients. This is the idea behind Safe Toys and Gifts Month, which sets aside ... good gifts for children. For companies that produce goods that fall into this category, ...
Breaking Medicine News(10 mins):